All lobbying filings
INNOVATIVE FEDERAL STRATEGIES, LLC
INNOVATIVE FEDERAL STRATEGIES, LLC filed a Q3 report for ACURX PHARMACEUTICALS, INC. on October 20, 2025, reporting $30,000 in lobbying income.
Lobbying for ACURX PHARMACEUTICALS, INC. · biopharmaceutical company
Filing · LD-2 quarterly report
Q3 report
Reporting period
3rd Quarter 2025
July 1 - Sep 30 · Posted Oct 20, 2025
Income
$30,000
What the client paid this registrant for the period.
Client based in
New York
Government bodies contacted
4
Lobbying activity
2
H.R.4026/S.2572, Department of Defense Appropriations Bill, 2026, Title IV, all provisions related to biodefense preparedness. H.R.5304/S.2587, Departments of Labor, Health and Human Services, Education, and Related Agencies Appropriations bill, Title II, all provisions related research and clinical trials for the development of antibiotics for infections caused by bacteria listed as priority pathogens.
H.R.3838/S.2296, National Defense Authorization Act, 2026, Title II, all provisions related to biodefense preparedness.